GENE ONLINE|News &
Opinion
Blog

Daniel Ojeda

WRITTEN BY Daniel Ojeda

Phase 3 Trial Results Grant New Validity to Controversial Sputnik V Vaccine
2021-02-04
Gilead Aspires to Prolong Leadership in HIV Market, Launches Therapeutic Vaccine Quest with Gritstone
2021-02-03
Johnson & Johnson’s COVID-19 Vaccine Draws Mixed Reactions as it Registers 66% Efficacy
2021-01-31
Vir Biotech’s Investigational Antibody Therapy Shows Promise in 8-Patient Phase 1 HBV Trial
2021-01-27
Scientists Track Cancer cells’ Family Tree via CRISPR to Better Understand Metastasis
2021-01-25
Game-Changing Antiretroviral Regimen from ViiV Receives FDA Approval
2021-01-22
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
2021-01-21
JPM Healthcare Conference Highlights: Editas Upbeat about EDIT-101 Success, Verve Continues to Tackle Cholesterol
2021-01-15
Biogen to Explore Apple’s Wearable Devices to Monitor Cognitive Health Markers
2021-01-13
Sarepta’s Stocks Drop 50% Following Middling Trial Data for Gene Therapy
2021-01-11
Imara’s Sickle Cell Disease Therapy Impresses in Phase 2 Trial
2021-01-09
Amazon, Berkshire Hathaway, and JPMorgan Chase Backed Venture Set to Disrupt Healthcare is Now Ending
2021-01-07
Arcturus’ COVID Vaccine Moves to Phase 2 Trial in Singapore
2021-01-05
Roche Bags EU Nod for a Novel Delivery Method in Breast Cancer Treatment
2020-12-25
Servier Aims to Expand Portfolio for Hematological Cancers by Acquiring Agios
2020-12-23
1 … 5 6 7 8 9
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top